Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

SEER Summary Stage 2018 Extent Classification for Histiocytic Sarcoma, EOD v3.3 / NAACCR 2026

Choose the already documented extent pattern to map it to the SEER Summary Stage 2018 HemeRetic extent classification for pathology-confirmed histiocytic sarcoma, ICD-O-3 9755/3, at initial diagnosis.

Evidence-based context for fast calculator use

Purpose:
Records the source-defined localized, systemic, or unknown SEER HemeRetic extent for pathology-confirmed histiocytic sarcoma 9755/3 at initial diagnosis.
Population:
patients with suspected or confirmed histiocytic or hyperinflammatory disease matching the original criteria
Factors:
Externally documented extent pattern
HomeSEER Summary Stage 2018 Extent Classification for Histiocytic Sarcoma, EOD v3.3 / NAACCR 2026
Pin your most used calculators here by clicking the star in the dropdown.

SEER Summary Stage 2018 Extent Classification for Histiocytic Sarcoma, EOD v3.3 / NAACCR 2026

Clinical Context & Background

Choose the already documented extent pattern to map it to the SEER Summary Stage 2018 HemeRetic extent classification for pathology-confirmed histiocytic sarcoma, ICD-O-3 9755/3, at initial diagnosis. Coding identity, year, site, timing, and authoritative-source requirements are shown as guidance instead of repeated administrative form entries. The source lock is EOD v3.3 / NAACCR 2026.
SEER states that these HemeRetic histologies have no official staging system. Histiocytic sarcoma is represented as localized (EOD Primary Tumor 100; Summary Stage 1), systemic (700; 7), or unknown (999; 9). EOD Regional Nodes and EOD Mets are not applicable in this schema. CNS C700-C729 and intracranial gland C751-C753 use separate schemas.
The permanent route name is retained for compatibility, but Ann Arbor is historical context only. This implementation does not derive Ann Arbor, Lugano, AJCC, stage I-IV, prognosis, treatment, or an LCH classification. It is software implementation verification of the recorder contract, not clinical validation.
Formula Logic
Literal HemeRetic mapping: solitary/isolated -> EOD 100 and SS 1; systemic/multifocal/disseminated -> 700 and 7; unknown -> 999 and 9.

Reference Data

Submitted extent patternEOD Primary TumorSummary Stage 2018
Single / solitary / unifocal / isolated1001 - Localized
Systemic / multiple / multifocal / disseminated7007 - Systemic
Unknown / not documented9999 - Unknown

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • At initial diagnosis when pathology confirms histiocytic sarcoma 9755/3 and the applicable HemeRetic primary-site schema and extent are documented.

How To Interpret

  • Read the result as a registry extent classification: localized, systemic, or unknown.
  • Regional-node and metastasis EOD fields are not applicable in this HemeRetic schema.

What To Do Next

  • Confirm coding against the current SEER*RSA HemeRetic schema and the complete source record.

Limitations

  • No official stage I-IV system is implemented.
  • No Ann Arbor, Lugano, AJCC, prognosis, treatment, or LCH-risk inference.
  • CNS and intracranial-gland sites use separate schemas.

Validated Population

SEER HemeRetic software contract for histiocytic sarcoma 9755/3, diagnosis years 2018-2026.

Calculation verification history

Verified

  1. : Production browser revalidation

    • Five source-backed SEER HemeRetic recorder cases were exercised on the public production route through visible controls; all three extent mappings, required-input validation, and a repeat submission matched expectations.
    • No unexpected N/A, literal undefined value, stale control, or browser-console error was observed.
    Download latest production check (Excel)

    Case-level evidence is retained in validation/browser-revalidation/ann-arbor-histiocytic-disorder-staging-2026-08-03.json.

  2. : Production browser validation

    • Ten source-backed cases were exercised on the public production route through visible browser controls; 10/10 case records passed their expected-versus-observed assertions across 11 visible submissions.
    • Overall browser status: failed-console. medium: Production emitted minified React error #418 during route loads/reloads used by this run.
    • Case-level inputs, expected and observed results, reset/repeat behavior, failure reproductions, and console evidence are retained in the production-browser evidence record.

    Case-level production evidence is retained in validation/browser-production/ann-arbor-histiocytic-disorder-staging.json.

  3. : Input workflow simplified and revalidated

    • Reduced the public form to result-, branch-, unit-, and applicability-changing inputs; removed or consolidated non-scoring, administrative, and duplicate questions.
    • Preserved the verified calculation or report-interpretation logic, thresholds, model version, component logic, and supported result pathways behind strict deterministic adapters.
    • Passed the calculator-specific regression audit, adapter-parity and malformed-input checks, the 144-calculator input-quality audit, and the 43-calculator entry-burden audit.

  4. : Unsupported Ann Arbor identity retired

    • Preserved the permanent route while replacing unsupported Ann Arbor stage I-IV behavior with the official SEER HemeRetic extent framework.
    • Documented that HemeRetic has no official staging system for histiocytic sarcoma and that Ann Arbor is historical context only.

  5. : Extent calculation and scope corrected

    • Implemented the strict eight-key 9755/3 contract, exact eligible site ranges, diagnosis-year lock, initial-diagnosis gate, source provenance, and literal 100/700/999 to 1/7/9 mapping.
    • Removed favorable defaults, B-symptom and diaphragm logic, site-count staging, prognosis, treatment, and stage I-IV language.

  6. : Full implementation validation completed

    • Passed 2,048 deterministic assertions using a separately encoded literal source oracle.
    • Verified source boundaries, immutable inputs, UI/static contracts, generated assets, workbook/evidence mirrors, registry, ledger, glossary, and LCH isolation.

    Software implementation verification only; not clinical validation.

Verification confirms the calculator implementation against the cited model; it is not independent clinical validation, regulatory approval, or medical advice.

Found a possible issue? Report it to improve this calculator

Share This Calculator

Share:

Related Tools

Pediatric LCH Risk-Organ ClassificationHLH-2004 Diagnostic Criteria Calculator — Hemophagocytic LymphohistiocytosisHScore for Reactive HLH (2014)

Frequently Asked Questions

When should SEER Summary Stage 2018 Extent Classification for Histiocytic Sarcoma, EOD v3.3 / NAACCR 2026 be used?

Use it for patients with suspected or confirmed histiocytic or hyperinflammatory disease matching the original criteria when all required inputs and the intended clinical setting are confirmed.

Can SEER Summary Stage 2018 Extent Classification for Histiocytic Sarcoma, EOD v3.3 / NAACCR 2026 determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.